BioSpace’s Post

We all know of, or have heard of Humira, AbbVie's blockbuster for rheumatoid arthritis. It was arguably one of the most successful and best-selling drugs for many years. 20 years after being launched, it lost its patent in 2023. Since, 8 biosimilars have launched... Has this affected AbbVie's footprint in the market? In short.... NO! 1 year on, AbbVie is still holding 96% of the Humira/Adalimumab market according to the latest quarterly report from Samsung Bioepis. Its going to be interesting to see if in 1 year, the same market share is held by AbbVie. #humira #abbvie #pharmanews #pharmaupdates #biotechupdates #biosimilar #humirapatent

#MarketsWithBS | Pharma stocks surged after positive domestic and US market news. The 54th GST Council cut GST on cancer drugs—Trastuzumab Deruxtecan, Osimertinib, and Durvalumab—from 12% to 5%, boosting both patients and manufacturers. Details here👉 https://mybs.in/2dYtMND Shivam Tyagi #gst #markets #pharma #stockmarket

Semnur Pharmaceuticals is taking a major step forward with its $2.5B SPAC merger, aiming to bring its non-opioid sciatica treatment, Semdexa, to market. With FDA fast-track designation and promising phase 3 results, Semdexa could be a game-changer in pain management, offering long-term relief for sciatica patients—without the use of opioids. 💡 Key Insight - As opioid alternatives gain traction, Semdexa could fill a critical gap in treating lumbosacral radicular pain, with projected sales of up to $2B in just five years. 🤔 Question to Consider - How can innovative pain treatments like Semdexa reshape the pain management landscape and reduce opioid reliance? #Biotech #SPAC #PainManagement #Sciatica #OpioidAlternatives

What Factors Are Driving the Growth of the #NeuropathicPain Market? The growth of the neuropathic pain market is driven by the rising demand for pain management drugs, government initiatives to increase awareness, and a surge in clinical trials. For example, Algiax Pharmaceuticals' Phase 2a study update on AP-325 (NCT04429919) confirmed safety and progression, highlighting ongoing advancements in chronic neuropathic pain treatment. Want To Know More: https://lnkd.in/dMWbZ34P #NeuropathicPain #DrugDevelopment #ClinicalTrials #PainManagement #HealthcareInnovation

The interstitial cystitis drugs market is on a robust growth trajectory, projected to reach $1.67 billion by 2028. This expansion is fueled by increased attention to rare diseases, innovations in biopharmaceuticals, and regulatory support for orphan drugs. Key trends include advancements in diagnostics and the rise of targeted therapies, enhancing patient care and outcomes. Learn more about the interstitial cystitis drugs market: https://lnkd.in/g-5vF2ee . . . #interstitial #cystitis #drugs #medications #tbrc #thebusinessresearchcompany #marketresearch #marketintelligence

Focused On Second- And Third-Generation Opportunities In Cardiometabolic Drugs Market: Merck Merck Group emphasized its focus on second- and third-generation opportunities within the cardiometabolic drugs market, including weight-loss therapies, the Company stated on Tuesday. Davis' comments on Tuesday echo those from January, when he said showing outcomes for cardiovascular, diabetes and conditions other than weight management would make it easier for drugs to get insurance reimbursements. The weight-loss drug market is estimated to be worth about $150 billion in annual global sales by the early 2030s and is currently dominated by Novo Nordisk's Wegovy and Eli Lilly's Zepbound, both belonging to the GLP-1 class. GLP-1 drugs, which help slow digestion and reduce hunger by triggering a feeling of fullness, are now being studied to see whether they can improve health in other ways. Merck said earlier this year that it was seeking GLP-1 treatments with benefits beyond weight loss as the drugmaker develops its own candidate, efinopegdutide, for a type of serious fatty liver disease now known as metabolic dysfunction-associated steatohepatitis (MASH). Rob Davis #merck #mercknews #cardiometabolicdrug #weightlossdrug

I recently completed a comprehensive course and assessment on *'Drug Development: Combating Pain'* by the Open University. The course delved into the critical stages of the drug development process, particularly focusing on the challenges and innovations in pain management. It covered essential topics such as:📖 -the identification of potential drug targets -preclinical and clinical trials -understand the historical background to pain control -understand that opioids, steroids and NSAIDs ,all work at the molecular level The knowledge acquired will be beneficial for me in understanding how pharmaceutical interventions can improve patient outcomes, especially in pain management #theopenuniversity #openlearnbyopenuniversity #pharmacy #drugdevelopment #combatingpain #opoids #NSAID #steroids

Radiodermatitis Market Insights: Growth and Future Prospects The global radiodermatitis market is on a growth trajectory, driven by rising cancer rates and advancements in radiation therapy. With a projected CAGR of 5.8% from 2023 to 2030, the market offers significant opportunities for pharmaceutical companies, particularly in emerging markets. As awareness of radiodermatitis management increases, so does the demand for effective treatments. Companies focusing on innovative product development and strategic partnerships are likely to gain a competitive edge in this expanding market. Explore more insights in our latest report on the global radiodermatitis market:https://lnkd.in/dvhTdYPt #Radiodermatitis #CancerTreatment #HealthcareInnovation #MarketResearch

Our research initiative aimed to understand the current diagnostic tests, pharmaceutical interventions, and treatment modalities for Chronic Kidney Disease. Engaging Nephrologists, Urologists, and Laboratory Directors, we gathered invaluable feedback. These insights highlighted gaps and unmet needs in CKD management, guiding future advancements.     For research collaboration, email info@idr.co   Visit www.idr.co to learn more about our projects.   #healthcareresearch #CKD #medicalInnovation #mrx #marketresearch #competitiveintelligence #research #consulting #expertnetwork

🌟 Great Read! 🌟 The FDA is gearing up for significant decisions in 2024 that could reshape the treatment landscape for various conditions. Key drugs awaiting approval include Eli Lilly's donanemab for Alzheimer's, Madrigal's resmetirom for NASH, and Merck's sotatercept for pulmonary arterial hypertension. These decisions could bring new hope to patients with early Alzheimer's, severe genetic conditions, and more. Keeping an eye on these regulatory milestones will be crucial for stakeholders in the pharmaceutical industry. Read more on the upcoming FDA decisions [https://lnkd.in/dqhcS6SV] #Pharma #FDA #DrugApproval